Dual Binding Site Acetylcholinesterase Inhibitors: Potential New Disease-Modifying Agents for AD
Marı́a del Monte-Millán(Hospital General Universitario Gregorio Marañón), Miguel Medina(Baptist Hospital of Miami), Pilar Muñoz-Ruiz(Universitat de Barcelona), Celia de Austria(Universitat de Barcelona), Ana Martı́nez(Consejo Superior de Investigaciones Científicas), Rita Valenzuela(Biomedical Research Networking Center on Neurodegenerative Diseases), Isabel Dorronsoro(Instituto de Química Médica), Laura Rubio(Pontificia Universidad Católica Madre y Maestra), Paola Usán(Universitat de Barcelona), Esther García‐Palomero(Universitat de Barcelona)
Cited by 32
Related Papers
COVID-19: Drug Targets and Potential Treatments
|Journal of Medicinal Chemistry|2020|469
First Non-ATP Competitive Glycogen Synthase Kinase 3 β (GSK-3β) Inhibitors: Thiadiazolidinones (TDZD) as Potential Drugs for the Treatment of Alzheimer's Disease
|Journal of Medicinal Chemistry|2002|448
(untitled)
|Edinburgh Research Explorer|0|353
GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS
|Frontiers in Molecular Neuroscience|2011|348
Glycogen synthase kinase 3 (GSK‐3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation
|Medicinal Research Reviews|2002|334